Subjective Cognitive Impairment In A French Sample (P2.174)

OBJECTIVE: Neuropsychological characterization of Subjective Cognitive Impairment (SCI). BACKGROUND: SCI has been proposed to define early stages of Alzheimer9s Disease (AD), preceding Mild Cognitive Impairment (MCI), and AD by several years. SCI is characterized by subjective complaint only.The neuropsychological profile of SCI is assumed to be normal. However, there is a need to investigate the ability of neuropsychology tests to distinguish between normal aging, SCI, MCI and AD. DESIGN/METHODS: Among 4459 patients, followed in the Behavioral Neurology Department of Sainte Marguerite hospital in Marseille since 1998, we have selected a cohort of 1228 patients well characterized (514 AD, 401 MCI, 213 SCI). A subgroup of 658 patients, have been evaluated each six months from 5 years, to describe neuropsychology of early AD stages. This study presents the results of the analysis of 198 subjects [mean age=69.56 (10.15); mean MMSE=26.50 (2.76)]: 35 No Cognitive Impairment (NCI) subjects, 59 SCI, 70 MCI and 34 AD. The 4 groups have been defined using CDS, RL/RI16 total recall, ADAS-cog, Hippocampal MRI and ApoE. We administered the following neuropsychological battery : MMSE, GDS, MFQ, RAVLT, TMTA B, BNT, ISAACS, SPAN. Statistical analysis was performed using ANOVA, Fisher9s PLSD. RESULTS: Significant neuropsychological correlations were found: 1°) in NCI vs SCI for GDS (p=0.001), RAVLT delayed recall (p=0.0027), MFQ (p<0.0001), BNT (p=0.0029); 2°) In SCI vs MCI for MMSE (p=0.0001), RAVLT total recall (p<0.0001), delayed recall (p<0.0001) and recognition (p<0.0001).Finally correlations between NCI vs SCI and vs MCI was found only for RAVLT delayed recall [F (3.193)=51.15]. CONCLUSIONS: SCI can be distinguished from NCI with neuropsychological evaluation (GDS, RAVLT delayed recall, MFQ, BNT) . SCI differs from MCI by cognitive profile (MMSE, RAVLT total recall, RAVLT delayed recall and recognition). RAVLT delayed recall is the best test to delineate the 3 groups (NCI, SCI, and MCI). Our cross-sectional findings need to be confirmed by a larger multi-center cohort study. Study Supported by: Disclosure: Dr. Michel has nothing to disclose. Dr. Sambuchi has nothing to disclose. Dr. Geda has nothing to disclose. Dr. Muraccioli has nothing to disclose. Dr. Paban has nothing to disclose. Dr. Jouve has nothing to disclose. Dr. Sambuc has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Bartolin has nothing to disclose. Dr. Gallant has nothing to disclose. Dr. Saint Jean has nothing to disclose. Dr. Rouyer has nothing to disclose. Dr. Brosset has nothing to disclose. Dr. Azorin has nothing to disclose. Dr. Alescio-Lautier has nothing to disclose. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., and Janssen Alzheimer9s Immunotherapy. Dr. Petersen has received royalty payments from Oxford University Press.